Patents Assigned to NANJING MOLECULAR RESEARCH, INC.
  • Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
    Patent number: 9156874
    Abstract: This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 13, 2015
    Assignee: Nanjing Molecular Research, Inc.
    Inventors: Junbiao Chang, Qiang Huang, Runcong Liu, Zheng Wang
  • O-(substituted benzyl) phosphoramidate compounds and therapeutic use
    Patent number: 9095599
    Abstract: This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: August 4, 2015
    Assignee: Nanjing Molecular Research, Inc.
    Inventors: Junbiao Chang, Zheng Wang, Suping Zhou
  • 2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof
    Publication number: 20140315850
    Abstract: The present invention is made to fulfill the foregoing need. Since most of antiHN nucleosides are 2?,3?-dideoxynucleosides that have been proved to be excellent substrates of kinases for the phosphorylations. 2?,3?-Dideoxy-2,-a-fluoro-2?-{3-C-methyl-nucleosides can be considered as one unique class of 2?,3?-dideoxynucleosides to be good substrate of kinases because fluorine mimics hydrogen. It also can be considered as ribo-nucleosides to incorporate into RNA of HCV because 2?-fluorine-a mimics 2?-a-OH group.
    Type: Application
    Filed: July 19, 2012
    Publication date: October 23, 2014
    Applicant: Nanjing Molecular Research, Inc.
    Inventors: Qiang Huang, Suping Zhou, Junbiao Chang
  • O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE
    Publication number: 20140038916
    Abstract: This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs.
    Type: Application
    Filed: December 30, 2011
    Publication date: February 6, 2014
    Applicant: Nanjing Molecular Research, Inc.
    Inventors: Zheng Wang, Suping Zhou
  • DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS
    Publication number: 20130210757
    Abstract: This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: NANJING MOLECULAR RESEARCH, INC.
    Inventor: NANJING MOLECULAR RESEARCH, INC.